Table 4.
Characteristics of the matched study population in the second additional analyses
| LR‐based PSM (n = 30) | RF‐based PSM (n = 14) | ||||||
|---|---|---|---|---|---|---|---|
| CCRT | TKI | Standardized difference‡ | CCRT | TKI | Standardized difference‡ | ||
| Characteristic | Number (%)‡ or mean (SD) | Number (%)‡ or mean (SD) | Number (%)‡ or mean (SD) | Number (%)‡ or mean (SD) | |||
| Age | 62.93 (6.33) | 60.47 (13.31) | 0.237 | 54.43 (7.81) | 55.86 (7.49) | 0.187 | |
| Gender | |||||||
| Female | 9 (60) | 8 (53) | 0.135 | § | § | 0.302 | |
| Male | 6 (40) | 7 (47) | § | § | |||
| Residency region | |||||||
| Non‐north | 3 (20) | 4 (27) | 0.158 | § | § | ||
| North | 12 (80) | 11 (73) | § | § | |||
| Comorbidity | |||||||
| Without | 8 (53) | 6 (40) | 0.270 | 3 (43) | 3 (43) | 0 | |
| With† | 7 (47) | 9 (60) | 4 (57) | 4 (57) | |||
| Smoking history | |||||||
| Without | 9 (60) | 9 (60) | 0 | § | § | 0.354 | |
| With | 6 (40) | 6 (40) | § | § | |||
| Subtypes of stage IIIb | |||||||
| T3–4N3 | 6 (40) | 6 (40) | 0 | § | § | 0 | |
| others | 9 (60) | 9 (60) | § | § | |||
| Use of PET | |||||||
| Without | 7 (47) | 8 (53) | 0.134 | 4 (57) | 4 (57) | 0 | |
| With | 8 (53) | 7 (47) | 3 (43) | 3 (43) | |||
†
Modified Carlson comorbidity score ≥ 1.
‡
Rounded.
§
Exact numbers are not reported because the Health and Welfare Data Science Center database center policy is to avoid numbers in single cells ≤ 2.
CCRT, concurrent chemoradiotherapy; LR, logistic regression; PET, positron emission tomography; PSM, propensity‐score matching; RF, random forest; SD, standard deviation; TKI, tyrosine kinase inhibitor.